European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi’
REYKJAVIK, Iceland and LONDON, Nov. 4, 2024’ In a significant advancement for the biosimilars market, Alvotech (NASDAQ: ALVO), a global biotechnology company dedicated to developing biosimilar treatments for a variety of medical conditions, and Advanz Pharma, a UK-based pharmaceutical firm specializing in specialty and rare disease medicines, have announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for AVT05. This drug is Alvotech’s proposed biosimilar to Simponi (golimumab), a biologic currently prescribed for a range of chronic inflammatory diseases, including rheumatoid arthritis and ulcerative colitis.
The acceptance of AVT05’s MAA by the EMA marks a pioneering moment within the pharmaceutical industry, as this is believed to be the first application globally for a biosimilar candidate aimed at Simponi. The proprietary drug, developed by Janssen Pharmaceuticals, has a significant market presence, and the introduction of AVT05 is projected to drive competition, enhance patient access, and potentially lower treatment costs in the European region.
Receiving acceptance for our marketing authorization application represents a crucial step for both Alvotech and patients in need of innovative therapeutic options, stated David M. Vasil, CEO of Alvotech. We are committed to ensuring that high-quality biosimilar medicines become accessible to those who require them, and this acceptance underscores our dedication to improving healthcare delivery across Europe.
Alvotech, known for its robust pipeline of biosimilar candidates, has collaborated with Advanz Pharma to advance the development and commercialization of AVT05, leveraging Advanz’s expertise in the specialty pharmaceutical sector. With regulatory hurdles now in play, the biosimilar is anticipated to complete the approval process by the fourth quarter of 2025.
The growing biosimilars market is positioned to play a critical role in the changing landscape of healthcare, particularly in Europe, where patients face rising costs for biologic therapies. As the healthcare ecosystem evolves, the introduction of AVT05 and its potential market entry is expected to encourage further investment and innovation within the biosimilar space.
As biosimilars continue to gain traction among healthcare providers and patients alike, the EMA’s acceptance of AVT05 could signify a larger shift towards more affordable treatment options that maintain therapeutic efficacy, ultimately benefiting public health on a broader scale.
Comments